Featured Research

from universities, journals, and other organizations

Investigational ovarian cancer drug shows promise against platinum resistant disease

Date:
October 9, 2010
Source:
European Society for Medical Oncology
Summary:
A drug being developed as a treatment for ovarian cancer has shown single agent activity with durable disease control in some patients in a Phase-II clinical trial, an international research group has reported.

A drug being developed as a treatment for ovarian cancer has shown single agent activity with durable disease control in some patients in a Phase-II clinical trial, an international research group has reported.

Dr Ursula Matulonis from Dana-Farber Cancer Institute in the USA reported the results of the single-agent trial of the drug, called MLN8237, in a poster at the 35th Congress of the European Society for Medical Oncology (ESMO).

MLN8237 selectively inhibits an enzyme known as Aurora A kinase, which is a member of a family of kinase enzymes involved in normal cell division. Researchers have found that Aurora A kinase is over-expressed in some cancer cells, leading to growth of cancers.

"In epithelial ovarian cancer, Aurora A kinase has been reported to be frequently upregulated or overexpressed, and associated with worse clinical outcome," Dr Matulonis said. "This is why an effective Aurora A Kinase inhibitor is a potential new therapy to be used alone or in combination with other standard agents such as paclitaxel."

In addition to ovarian cancer, the Aurora A kinase gene is amplified or overexpressed, or both, in other cancers including colon, breast, pancreatic, and bladder cancers, as well as certain lymphomas, leukemias and myeloma.

Unlike other aurora kinase inhibitors currently being studied, MLN8237 selectively targets aurora A Kinase and can be administered orally, Dr Matulonis said.

In the current study, sponsored by Millennium Pharmaceuticals, American, French, Italian and Polish researchers treated 31 patients whose cancer was resistant or refractory to platinum-based chemotherapy and who had tried at least three other therapies. Twenty-five patients had ovarian cancer, 5 had primary peritoneal cancer, and one had Fallopian tube carcinoma.

"The patients enrolled to this study all had progression after platinum-containing regimens which is the mainstay of ovarian cancer treatment," Dr Matulonis said. "Patients with 'platinum resistant' recurrent ovarian cancer represent a large unmet medical need."

The patients received MLN8237 in 21-day cycles: seven days of twice-daily 50mg treatment, followed by a 14-day break. Three patients had a partial response to the treatment, and 5 had stable disease that was sustained for at least four 21-week cycles, the researchers report.

"The most important finding from this study was the fact that MLN8237 demonstrates single-agent activity in ovarian cancer with encouraging durable disease control in some patients," Dr Matulonis said.

Several patients have remained on the study drug for over 12 months, she noted. "I personally have a patient on this current study who has been on MLN8237 for now more than 12 months. She is doing remarkably well."

The fact that multiple patients had stable disease or response suggests that future development of MLN8237 in combination with other active agents may be a promising avenue to investigate, the researchers said.

"These durable responses are encouraging since all of the patients enrolled on this study have failed platinum. Because of the other durable responses reported in other MLN8237 studies, this all helps support the prediction that this is a new mechanism to fight cancer, and the MLN8237 drug does not appear to share mechanisms for resistance to other available drugs."

The researchers noted that the drug had various toxicities. The most common serious toxicities included neutropenia, stomatitis, leucopenia, thrombocytopenia and fatigue, which were generally reversible during the 14-day break in treatment. Five patients discontinued due to adverse events.

The fact that the drug has shown some efficacy in treating drug-resistant ovarian cancer "is worth exploring further," noted Professor Stan Kaye, Professor of Medical Oncology at the Royal Marsden Hospital.


Story Source:

The above story is based on materials provided by European Society for Medical Oncology. Note: Materials may be edited for content and length.


Cite This Page:

European Society for Medical Oncology. "Investigational ovarian cancer drug shows promise against platinum resistant disease." ScienceDaily. ScienceDaily, 9 October 2010. <www.sciencedaily.com/releases/2010/10/101009082827.htm>.
European Society for Medical Oncology. (2010, October 9). Investigational ovarian cancer drug shows promise against platinum resistant disease. ScienceDaily. Retrieved August 27, 2014 from www.sciencedaily.com/releases/2010/10/101009082827.htm
European Society for Medical Oncology. "Investigational ovarian cancer drug shows promise against platinum resistant disease." ScienceDaily. www.sciencedaily.com/releases/2010/10/101009082827.htm (accessed August 27, 2014).

Share This




More Health & Medicine News

Wednesday, August 27, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

WHO Calls for Ban on E-Cigarette Sales to Minors

WHO Calls for Ban on E-Cigarette Sales to Minors

AFP (Aug. 26, 2014) The World Health Organization called Tuesday on governments should ban the sale of e-cigarettes to minors, warning that they pose a "serious threat" to foetuses and young people. Duration: 01:44 Video provided by AFP
Powered by NewsLook.com
Have You Ever Been 'Sleep Drunk?' 1 in 7 Has

Have You Ever Been 'Sleep Drunk?' 1 in 7 Has

Newsy (Aug. 26, 2014) A study published in the journal "Neurology" interviewed more than 19,000 people and found 15 percent suffer from being "sleep drunk." Video provided by Newsy
Powered by NewsLook.com
Does Medical Marijuana Reduce Painkiller Overdose Deaths?

Does Medical Marijuana Reduce Painkiller Overdose Deaths?

Newsy (Aug. 26, 2014) A new study found fewer deaths from prescription drug overdoses in states that have legalized medical marijuana. But experts disagree on the results. Video provided by Newsy
Powered by NewsLook.com
Official: British Ebola Sufferer Receiving Experimental Drug

Official: British Ebola Sufferer Receiving Experimental Drug

AFP (Aug. 26, 2014) A British nurse infected with Ebola while working in Sierra Leone is being given the same experimental drug used on two US missionaries who have recovered for the disease, doctors in London say. Duration: 00:44 Video provided by AFP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

    Environment News

    Technology News



    Save/Print:
    Share:

    Free Subscriptions


    Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

    Get Social & Mobile


    Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

    Have Feedback?


    Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
    Mobile: iPhone Android Web
    Follow: Facebook Twitter Google+
    Subscribe: RSS Feeds Email Newsletters
    Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins